SCHEMBL3046946

SCHEMBL3046946

CCN(CC1CCCC1)c1cc(F)ccc1C=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GRIN2A Q12879 7/20 0.38
GRIA2 P42262 5/20 0.38
ALDH1A3 P47895 1/20 0.35
ADH1C P00326 1/20 0.33
ADH1A P07327 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SRC P12931 1/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
ALDH3A1 P30838 1/20 0.32
GRIN1 Q05586 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3036495 0.90 GRIA2 (0.38) ALDH1A1L3MBTL1GRIN2AGRIA2ALDH1A3
SCHEMBL3041869 0.85 ALDH1A1 (0.35) ALDH1A1L3MBTL1GRIN2AGRIA2ALDH1A3
SCHEMBL3043051 0.84 ALDH1A3 (0.40) ALDH1A1L3MBTL1ALDH1A3KDM4EMEN1
SCHEMBL3043965 0.84 PSEN1 (0.39) ALDH1A1L3MBTL1ALDH1A3MEN1KMT2A
SCHEMBL3044441 0.84 CSNK1D (0.39) ALDH1A1L3MBTL1ALDH1A3RAB9APOLB
SCHEMBL3039488 0.82 ALDH1A1 (0.46) ALDH1A1L3MBTL1SLC6A2SLC6A4KDM4E
SCHEMBL3043759 0.81 SRC (0.38) ALDH1A1L3MBTL1ALDH1A3ADH1CADH1A
SCHEMBL4189946 0.79 ALDH1A1 (0.40) ALDH1A1L3MBTL1GRIN2AGRIA2KDM4E
SCHEMBL3539336 0.77 NPC1 (0.34) ALDH1A1L3MBTL1ALDH1A3ADH1CADH1A
SCHEMBL3545615 0.77 CNR1 (0.33) ALDH1A1L3MBTL1ALDH1A3ADH1CADH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2149563-B9 NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND KOWA CO (JP) 2015-04-22 EP disclosed
EP-2149563-B1 NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND KOWA CO (JP) 2015-01-07 EP disclosed
CN-101679309-B Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound KOWA CO 2012-02-29 CN disclosed
CN-101679309-A Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound KOWA CO 2010-03-24 CN disclosed
US-7659271-B2 Pyrimidine compound having dibenzylamine structure and medicament comprising the same KOWA COMPANY, LTD. (JP) 2010-02-09 US disclosed
EP-2149563-A1 NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND Kowa Company. Ltd. (JP) 2010-02-03 EP disclosed
US-20090082352-A1 N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) KOWA COMPANY, LTD. (JP) 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082352-A1 N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) CETP, NPC1L1, MTTP ALDH1A1 4452/4885L3MBTL1 179/4885GRIN2A 3874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.